Ipca Laboratories Ltd
Ipca Laboratories Ltd (IPCALAB) last traded at ₹1,921, a market capitalisation of ₹48,737 crore, on a P/E of 35.5. Over the past 52 weeks the stock has ranged between ₹1,252 and ₹1,957. Ipca Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2,788 crore and net profit of ₹424 crore. Figures are as of 25 Aug 2026 and are not real time.
Ipca Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Ipca Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,788 cr, up 20.7% from ₹2,309 cr a year earlier. Net profit was ₹424 cr, up 82.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | 2,788 |
| Expenses | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | 2,119 |
| Operating profit | 441 | 463 | 429 | 416 | 545 | 533 | 484 | 670 |
| OPM % | 19% | 21% | 19% | 18% | 21% | 22% | 20% | 24% |
| Other income | 26 | 20 | -179 | 33 | -30 | 38 | 48 | 25 |
| Interest | 23 | 17 | 22 | 19 | 20 | 18 | 20 | 12 |
| Depreciation | 100 | 98 | 100 | 100 | 103 | 108 | 107 | 111 |
| Profit before tax | 345 | 368 | 128 | 331 | 392 | 446 | 404 | 572 |
| Tax % | 29% | 25% | 49% | 29% | 28% | 18% | 24% | 26% |
| Net profit | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| EPS (₹) | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ipca Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 5,395 | 5,797 | 6,204 | 7,662 | 8,897 | 9,599 | 10,126 |
| Operating profit | 1,552 | 1,325 | 932 | 1,324 | 1,731 | 1,990 | 2,232 |
| OPM % | 29% | 23% | 15% | 17% | 19% | 21% | 22% |
| Net profit | 1,141 | 890 | 479 | 523 | 785 | 1,184 | 1,375 |
| EPS (₹) | 44.94 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 | 51.63 |
TTM is the trailing twelve months to the most recent quarter.
Ipca Laboratories Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 11%
- 10 Years
- 30%
- 5 Years
- 1%
- 3 Years
- 37%
- TTM
- 54%
- 10 Years
- 21%
- 5 Years
- 9%
- 3 Years
- 30%
- 1 Year
- 37%
- 10 Years
- 14%
- 5 Years
- 13%
- 3 Years
- 13%
- Last Year
- 16%
Ipca Laboratories Ltd shareholding pattern
Promoters held 44.72% at Jun 2026, broadly unchanged since Jun 2025. FIIs 10.72% and DIIs 37.04%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.30% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
| FIIs | 10.83% | 11.06% | 10.75% | 10.67% | 10.42% | 10.62% | 10.63% | 10.72% |
| DIIs | 33.90% | 35.36% | 35.73% | 35.88% | 36.45% | 36.99% | 37.13% | 37.04% |
| Government | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
| Public | 8.64% | 8.53% | 8.45% | 8.41% | 8.09% | 7.33% | 7.21% | 7.19% |
| No. of shareholders | 82,975 | 90,189 | 88,306 | 85,582 | 82,870 | 77,673 | 82,184 | 82,060 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ipca Laboratories Ltd corporate filings
- Transcript of Conference CallCompany Updatelow impact
Cruxal's analysis: Ipca Laboratories has filed the transcript of its analyst/investor conference call…
Read the full analysis - Audiolink for Conference Call held on 14.08.2026Company Updatelow impact
Cruxal's analysis: Ipca Laboratories has made the audio recording of its investor and analyst conference…
Read the full analysis - Copy of Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Ipca Laboratories Ltd has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - 76th AGM - Voting Results and Scrutinizer ReportAGM/EGMlow impact
Cruxal's analysis: Ipca Laboratories Limited has successfully concluded its 76th Annual General Meeting held…
Read the full analysis - Proceedings of AGMAGM/EGMlow impact
Cruxal's analysis: Ipca Laboratories Limited has successfully concluded its 76th Annual General Meeting held…
Read the full analysis - Standalone and Consolidated Unaudited Financial Results for Q1FY27Board Meetinghigh impact
Cruxal's analysis: Ipca Laboratories Limited reported robust Q1 FY27 financial results, with consolidated…
Read the full analysis - Conference Call to discuss Q1FY27 ResultsCompany Updatelow impact
Cruxal's analysis: Ipca Laboratories Limited has announced that it will host an earnings conference call on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Ipca Laboratories Ltd
Cruxal reads every Ipca Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.